Lundbeckfonden Ventures and Chiesi Ventures have once again invested in the ocular oncology therapy developer, which has now raised $191m in total.
Aura Biosciences, a US-based developer of treatments for eye cancer, raised $80m on Monday from investors including Lundbeckfonden Ventures and Chiesi Ventures, on behalf of pharmaceutical firms Lundbeck and Chiesi Group respectively.
Matrix Capital Management and Surveyor Capital co-led the round, which also featured Rock Springs Capital, Adage Capital Management, Velosity Capital, Medicxi, Advent Life Sciences, Arix Bioscience, Columbus Venture Partners and Ysios Capital.
Founded in 2009, Aura is developing virus-like drug conjugates designed to target and destroy specific cancer…
